<DOC>
	<DOC>NCT00189644</DOC>
	<brief_summary>The main objective of this randomized trial is to compare 6 FEC100 to 4 FEC100 + 4 Taxol in patients with resected node positive breast cancer. Main endpoint is disease free survival. Secondary endpoints are overall survival, time to local recurrence, time to distant metastases, and tolerance. A total of 840 patients have been included in the trial.</brief_summary>
	<brief_title>6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologically proven cancer of the breast, Mastectomy or complete tumorectomy, Histologically proven homolateral, axillary lymph node involvement (at least 1 N+) Period between surgery (second operation in case of primarily incomplete resection) and the start of chemotherapy &lt; 2 months, Biological criteria (before the first FEC cycle): Neutrophils &gt;1.5 109 /L Platelets &gt;100 109/L Hemoglobin &gt;10 g/dl Creatininemia &lt;120 mmol/1 Bilirubinemia &lt;1.5 Upper normal value Female patients over 18 years old Written and signed informed consent Performance Status less than or equal to 2 (WHO scale, see Annex IV) Prior chemotherapy or radiotherapy, including neoadjuvant treatment for cancer of the breast, Bilateral breast cancer or history of contralateral breast cancer Cardiac history: cardiac insufficiency (LVEF &lt;50%) or coronary decompensation Pregnancy and breastfeeding (effective contraception is mandatory in the case of women of childbearing potential) Inflammatory breast cancer Distant metastasis or supraclavicular adenopathy Benign pathology or history of malignant pathology accompanied by a life expectancy of less than two years Contraindication to Anthracyclines, Cyclophosphamide, 5FU or Taxol Psychiatric pathology Patient participating in another trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>